Two Seas Capital’s Immunovant IMVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$79.5M Buy
3,201,962
+335,000
+12% +$8.67M 1.11% 15
2025
Q4
$72.9M Buy
2,866,962
+104,922
+4% +$2.34M 1.5% 13
2025
Q3
$44.5M Buy
2,762,040
+509,268
+23% +$8.24M 0.71% 16
2025
Q2
$36M Buy
2,252,772
+610,000
+37% +$9.22M 0.61% 16
2025
Q1
$28.1M Buy
1,642,772
+131,158
+9% +$2.74M 0.88% 14
2024
Q4
$37.4M Buy
1,511,614
+835,000
+123% +$23.7M 3.24% 12
2024
Q3
$19.3M Sell
676,614
-15,792
-2% -$466K 3.13% 10
2024
Q2
$18.3M Buy
692,406
+151,111
+28% +$4.3M 2.97% 9
2024
Q1
$17.5M Buy
541,295
+342,543
+172% +$12.5M 3.43% 4
2023
Q4
$8.37M Sell
198,752
-228,504
-53% -$8.41M 2.04% 8
2023
Q3
$16.4M Buy
+427,256
New +$9.66M 3.3% 4

Other funds holding IMVT

Two Seas Capital's IMVT Position: Q1 2026 in Review

Two Seas Capital increased its Immunovant (IMVT) stake by 12% in Q1 2026, buying an estimated $8.67M and bringing the position to 3,201,962 shares worth $79.5M. The position accounts for 1.11% of the portfolio, ranked #15.

Two Seas Capital first reported a position in IMVT in Q3 2023 and has held it in 11 quarters since. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Two Seas Capital held 3,201,962 shares of Immunovant worth $79.5M as of Q1 2026.
  • Two Seas Capital bought 335,000 Immunovant shares in Q1 2026, an estimated $8.67M.
  • Immunovant made up 1.11% of Two Seas Capital's portfolio in Q1 2026, its #15 holding.
  • Two Seas Capital first reported a position in Immunovant in Q3 2023 and has held it in 11 quarters since.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Two Seas Capital's 13F filing for Q1 2026, filed 15 May 2026.